Arturo Llobell-Uriel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Arturo Llobell-Uriel has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Adrian Martín-Gutiérrez
Department of Rheumatology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain
1 shared publication- Albert Pérez-Isidro
Department of Immunology, Centre de Diagnòstic Biomèdic, Hospital Clínic de Barcelona, Villarroel 170-Escala 4, Planta 0, 08036 Barcelona, Spain
1 shared publication Almudena García-Castaño
Department of Oncology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain
1 shared publicationAntoni Berenguer-Llergo
Department of Rheumatology, Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona Medicine Department, Sabadell, Spain
1 shared publicationAntonio Gómez-Centeno
Department of Rheumatology, Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí (I3PT-CERCA), Universitat Autònoma de Barcelona Medicine Department, Sabadell, Spain
1 shared publicationCarmen Secada-Gómez
Department of Rheumatology, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Rheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study
To describe the frequency, clinical spectrum, and management of rheumatic immune-related adverse events (R-irAEs) in patients receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain. This was a retrospective, observational study involving 734 patients treated with ICIs between January 2016 and December 2022 in two Spanish hospitals. Electronic medical records were systematically reviewed to identify R-irAEs, with diagnoses confirmed by rheumatologists. The data collected included demographics, cancer type, ICI regimen, time to R-irAE onset, clinical features, management, and outcomes. Among the 734 patients, 227 (30.9%) developed any irAEs, with 54 (7.35%) presenting R-irAEs, accounting for 23.8% of all irAEs. The most common cancers were lung cancer and melanoma. Most R-irAEs occurred within six months of ICI initiation. The most frequent manifestations were polymyalgia rheumatica (n = 12) and various forms of arthritis/arthralgia (n = 26). Myositis is a particularly severe manifestation that presents at the first or second cycle of treatment. Corticosteroids are the primary treatment, with some patients requiring immunosuppressants, biologics, or intravenous immunoglobulins. Clinical improvement was observed in 88% of the treated patients, although 18 patients required ICI discontinuation due to toxicity. The increasing use of ICIs in cancer treatment is limited by development of irAEs (30.9%) and R-irAEs (7.35%) accounting for 23.8% of irAEs. Prompt recognition and multidisciplinary management, including rheumatology input, are essential to optimize patient outcomes and balance the continuation of cancer treatment. Greater awareness and standardized guidelines are needed to improve the diagnosis and care of these adverse events.
- 11 March 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessRheumatic immune-related adverse effects of immune checkpoint treatment: a retrospective multicentre study
To describe the frequency, clinical spectrum, and management of rheumatic immune-related adverse events (R-irAEs) in patients receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain. This was a retrospective, observational study involving 734 patients treated with ICIs between January 2016 and December 2022 in two Spanish hospitals. Electronic medical records were systematically reviewed to identify R-irAEs, with diagnoses confirmed by rheumatologists. The data collected included demographics, cancer type, ICI regimen, time to R-irAE onset, clinical features, management, and outcomes. Among the 734 patients, 227 (30.9%) developed any irAEs, with 54 (7.35%) presenting R-irAEs, accounting for 23.8% of all irAEs. The most common cancers were lung cancer and melanoma. Most R-irAEs occurred within six months of ICI initiation. The most frequent manifestations were polymyalgia rheumatica (n = 12) and various forms of arthritis/arthralgia (n = 26). Myositis is a particularly severe manifestation that presents at the first or second cycle of treatment. Corticosteroids are the primary treatment, with some patients requiring immunosuppressants, biologics, or intravenous immunoglobulins. Clinical improvement was observed in 88% of the treated patients, although 18 patients required ICI discontinuation due to toxicity. The increasing use of ICIs in cancer treatment is limited by development of irAEs (30.9%) and R-irAEs (7.35%) accounting for 23.8% of irAEs. Prompt recognition and multidisciplinary management, including rheumatology input, are essential to optimize patient outcomes and balance the continuation of cancer treatment. Greater awareness and standardized guidelines are needed to improve the diagnosis and care of these adverse events.
- Open Access
- 6 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1295
Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients
Anti-dsDNA autoantibodies quantification and complement levels are widely used to monitor disease activity in systemic lupus erythematosus (SLE). However, better biomarkers are still needed. We hypothesised whether the dsDNA antibody-secreting B-cells could be a complementary biomarker in disease activity and prognosis of SLE patients. Fifty-two SLE patients were enrolled and followed for up to 12 months. Additionally, 39 controls were included. An activity cut-off (comparing active and non-active patients according to clinical SLEDAI-2K) was established for SLE-ELISpot, chemiluminescence and Crithidia luciliae indirect immunofluorescence tests (≥11.24, ≥374.1 and ≥1, respectively). Assays performances together with complement status were compared regarding major organ involvement at the inclusion and flare-up risk prediction after follow-up. SLE-ELISpot showed the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and, after follow-up, with an increased hazard ratio for disease flare-up (3.4) and especially renal flare (6.5). Additionally, the combination of hypocomplementemia and high SLE-ELISpot results increased those risks up to 5.2 and 32.9, respectively. SLE-ELISpot offers complementary information to anti-dsDNA autoantibodies to evaluate the risk of a flare-up in the following year. In some cases, adding SLE-ELISpot to the current follow-up protocol for SLE patients can improve clinicians’ personalised care decisions.
- 6 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (4) , 1295
Open AccessAnti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients
Anti-dsDNA autoantibodies quantification and complement levels are widely used to monitor disease activity in systemic lupus erythematosus (SLE). However, better biomarkers are still needed. We hypothesised whether the dsDNA antibody-secreting B-cells could be a complementary biomarker in disease activity and prognosis of SLE patients. Fifty-two SLE patients were enrolled and followed for up to 12 months. Additionally, 39 controls were included. An activity cut-off (comparing active and non-active patients according to clinical SLEDAI-2K) was established for SLE-ELISpot, chemiluminescence and Crithidia luciliae indirect immunofluorescence tests (≥11.24, ≥374.1 and ≥1, respectively). Assays performances together with complement status were compared regarding major organ involvement at the inclusion and flare-up risk prediction after follow-up. SLE-ELISpot showed the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and, after follow-up, with an increased hazard ratio for disease flare-up (3.4) and especially renal flare (6.5). Additionally, the combination of hypocomplementemia and high SLE-ELISpot results increased those risks up to 5.2 and 32.9, respectively. SLE-ELISpot offers complementary information to anti-dsDNA autoantibodies to evaluate the risk of a flare-up in the following year. In some cases, adding SLE-ELISpot to the current follow-up protocol for SLE patients can improve clinicians’ personalised care decisions.